RxDoctor Payments DataLook up a doctor →

Lavinia Drambarean, PA

Physician Assistant · Hattiesburg, MSNPI 1871849372

Payments from drug & device makers

$381,569in general payments, 2019–2025

Across 1,555 payments — averaging $245.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$141K
  • Lilly USA, LLC$55K
  • AbbVie$53K
  • E.r. Squibb & Sons, L.L.C.$38K
  • Regeneron Healthcare Solutions, Inc.$28K
  • Incyte Corporation$25K
  • plus $41K from 34 others

What the payments were for

  • Consulting fees$23,3956%
  • Speaking & faculty fees$241,41863%
  • Travel & lodging$89,26023%
  • Food & beverage$26,8717%
  • Education$6250%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$381,569 in reported general payments places this provider in the 95th percentile of 278 physician assistant providers in Mississippi.

See all physician assistant providers in Mississippi

Medicare billing

Part B allowed, 2024
$83,638
Medicare patients
322
Services billed
2,445

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Skyrizi PenRisankizumab-Rzaa15$324,990
RinvoqUpadacitinib35$220,173
Dupixent PenDupilumab49$193,467
Taltz AutoinjectorIxekizumab13$89,353
Ketoconazole213$5,035
Betamethasone Valerate154$4,634
Metronidazole25$1,930
Tacrolimus25$1,919
Dutasteride54$1,630
Betamethasone Dipropionate26$1,480
Clobetasol Propionate18$1,394
Clindamycin Phosphate30$1,242
Triamcinolone Acetonide88$1,181
Hydroxychloroquine Sulfate25$1,040
Tretinoin16$748

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRinvoq$53,021$220,17335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 278 physician assistant providers in Mississippi.

Other physician assistant in Hattiesburg

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →